Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, and its majority-owned subsidiary, Baergic Bio, Inc. (“Baergic”), announce that Avenue has entered into an agreement for Baergic to be acquired by Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome”), including the global rights to BAER-101 (also known as AZD7325), a novel oral GABAA α2,3 subtype-selective receptor positive allosteric modulator (PAM). BAER-101 was originally licensed by Baergic from AstraZeneca AB (“AstraZeneca”) and will be referred to as AXS-17 by Axsome going forward.
Read the full article: Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics //
Source: https://www.globenewswire.com/news-release/2025/11/06/3182367/0/en/Avenue-Therapeutics-Announces-Acquisition-of-Subsidiary-Baergic-Bio-by-Axsome-Therapeutics.html